PRLD (Prelude Therapeutics) Cash Flow from Others: $0.61 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PRLD Prelude Therapeutics Inc PRLD
30 GF Score
Price $6.62
! 5 Warning Signs
View Full Analysis

What is Prelude Therapeutics Cash Flow from Others?

Prelude Therapeutics PRLD +2.16% 30 Cash Flow from Others is $0.61 Mil as of Jun. 2026. GuruFocus rates PRLD with a GF Score™ of 30/100. The stock has 5 warning signs investors should review.

Prelude Therapeutics's cash flow from others for the three months ended in Jun. 2026 was $0.08 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Jun. 2026 was $0.61 Mil.

Prelude Therapeutics Cash Flow from Others Related Terms

Prelude Therapeutics Cash Flow from Others Historical Data

* Premium members only.

The historical data trend for Prelude Therapeutics's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prelude Therapeutics Cash Flow from Others Chart

Prelude Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Others
Get a 7-Day Free Trial 2.69 4.31 -1.54 -3.05 1.16

Prelude Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.33 0.20 -0.00 0.08
PRLD
30GF Score
Prelude Therapeutics Inc PRLD
Cash Flow from Others is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prelude Therapeutics Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.61 Mil.

Frequently Asked Questions Learn more about Cash Flow from Others →
What does a Cash Flow from Others of $0.61 Mil mean?
Prelude Therapeutics (PRLD) has a Cash Flow from Others of $0.61 Mil as of Jun. 2026. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for Prelude Therapeutics and its competitors.
Is Prelude Therapeutics' Cash Flow from Others too high?
Prelude Therapeutics' current Cash Flow from Others is $0.61 Mil. Overall, Prelude Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' Cash Flow from Others compare to PROK and ZNTL?
Prelude Therapeutics' Cash Flow from Others of $0.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Others for a Biotechnology company?
A good Cash Flow from Others depends on the Biotechnology industry context. However, Cash Flow from Others should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Others mean?
A high Cash Flow from Others can signal that a stock is expensive relative to its fundamentals. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for Prelude Therapeutics and its competitors. Prelude Therapeutics's current Cash Flow from Others is $0.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current Cash Flow from Others of $0.61 Mil. The current Cash Flow from Others is $0.61 Mil. Prelude Therapeutics' overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Others calculated?
Cash Flow from Others is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current Cash Flow from Others is $0.61 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prelude Therapeutics Business Description

Address 175 Innovation Boulevard, Wilmington, DE, USA, 19805
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
30GF Score

Get the complete analysis for PRLD

Cash Flow from Others is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.62
Price